Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer
Sunshine Biopharma (NASDAQ:SBFM) has appointed Michel Roy as its new Chief Commercial Officer (CCO), effective immediately. Mr. Roy brings over 20 years of pharmaceutical industry experience and will oversee the company's commercial strategy, including sales, marketing, and business development.
From 2020 to 2024, Roy founded and led Canadian operations for Shilpa Medicare , and previously served as Vice President of Business Development and Sales at Intas Pharmaceuticals (2014-2020). He holds an Executive MBA from John Molson School of Business, an M.Sc. from Université de Montréal, and a Bachelor of Commerce in economics from Concordia University.
Roy's expertise spans licensing, sales, regulatory affairs, operations, and program management in the pharmaceutical and biotechnology sectors. Dr. Steve Slilaty, CEO of Sunshine Biopharma, expressed confidence that Roy's strategic vision and experience will be important for the company's growth and market expansion.
Sunshine Biopharma (NASDAQ:SBFM) ha nominato Michel Roy come nuovo Chief Commercial Officer (CCO), con effetto immediato. Il signor Roy porta con sé oltre 20 anni di esperienza nell'industria farmaceutica e supervisionerà la strategia commerciale dell'azienda, inclusi vendita, marketing e sviluppo commerciale.
Dal 2020 al 2024, Roy ha fondato e guidato le operazioni canadesi per Shilpa Medicare e in precedenza ha ricoperto il ruolo di Vice Presidente dello Sviluppo Commerciale e delle Vendite presso Intas Pharmaceuticals (2014-2020). Ha conseguito un Executive MBA presso la John Molson School of Business, un M.Sc. presso l'Université de Montréal, e una Laurea in Economia presso la Concordia University.
La competenza di Roy spazia dalla concessione di licenze, vendita, affari regolatori, operazioni e gestione di programmi nei settori farmaceutico e biotecnologico. Il Dr. Steve Slilaty, CEO di Sunshine Biopharma, ha espresso fiducia che la visione strategica e l'esperienza di Roy saranno importanti per la crescita e l'espansione nel mercato dell'azienda.
Sunshine Biopharma (NASDAQ:SBFM) ha nombrado a Michel Roy como su nuevo Chief Commercial Officer (CCO), con efecto inmediato. El Sr. Roy aporta más de 20 años de experiencia en la industria farmacéutica y supervisará la estrategia comercial de la empresa, incluyendo ventas, marketing y desarrollo empresarial.
Desde 2020 hasta 2024, Roy fundó y lideró las operaciones canadienses de Shilpa Medicare, y anteriormente se desempeñó como Vicepresidente de Desarrollo de Negocios y Ventas en Intas Pharmaceuticals (2014-2020). Tiene un Executive MBA de la John Molson School of Business, un M.Sc. de la Université de Montréal, y una Licenciatura en Comercio en economía de la Concordia University.
La experiencia de Roy abarca licencias, ventas, asuntos regulatorios, operaciones y gestión de programas en los sectores farmacéutico y biotecnológico. El Dr. Steve Slilaty, CEO de Sunshine Biopharma, expresó confianza en que la visión estratégica y la experiencia de Roy serán importantes para el crecimiento y la expansión de mercado de la empresa.
Sunshine Biopharma (NASDAQ:SBFM)가 미셸 로이를 새로운 최고상업책임자 (CCO)로 즉시 임명했습니다. 로이 씨는 제약 산업에서 20년 이상의 경험을 가지고 있으며, 회사의 상업 전략, 판매, 마케팅 및 비즈니스 개발을 감독할 것입니다.
2020년부터 2024년까지 로이는 Shilpa Medicare의 캐나다 운영을 설립하고 이끌었으며, 이전에는 Intas Pharmaceuticals(2014-2020)에서 비즈니스 개발 및 판매 부사장으로 재직했습니다. 그는 John Molson 경영대학원에서 Executive MBA를, 몬트리올 대학교에서 M.Sc.를, 콘코리아 대학교에서 경제학 학사 학위를 취득했습니다.
로이 씨의 전문성은 제약 및 생명공학 분야에서 라이센스, 판매, 규제 문제, 운영 및 프로그램 관리에 걸쳐 있습니다. Sunshine Biopharma의 CEO인 스티브 슬릴라티 박사는 로이 씨의 전략적 비전과 경험이 회사의 성장과 시장 확장에 중요할 것이라고 확신을 표시했습니다.
Sunshine Biopharma (NASDAQ:SBFM) a nommé Michel Roy comme nouveau Chief Commercial Officer (CCO), avec effet immédiat. M. Roy apporte plus de 20 ans d'expérience dans l'industrie pharmaceutique et supervisera la stratégie commerciale de l'entreprise, y compris les ventes, le marketing et le développement commercial.
De 2020 à 2024, Roy a fondé et dirigé les opérations canadiennes de Shilpa Medicare, et a précédemment été vice-président du développement commercial et des ventes chez Intas Pharmaceuticals (2014-2020). Il est titulaire d'un Executive MBA de la John Molson School of Business, d'un M.Sc. de l'Université de Montréal, et d'une Licence en commerce en économie de l'Université Concordia.
L'expertise de Roy couvre les licences, les ventes, les affaires réglementaires, les opérations et la gestion de programmes dans les secteurs pharmaceutique et biotechnologique. Le Dr Steve Slilaty, PDG de Sunshine Biopharma, a exprimé sa confiance quant au fait que la vision stratégique et l'expérience de Roy seront essentielles à la croissance et à l'expansion de l'entreprise sur le marché.
Sunshine Biopharma (NASDAQ:SBFM) hat Michel Roy als neuen Chief Commercial Officer (CCO) mit sofortiger Wirkung ernannt. Herr Roy bringt über 20 Jahre Erfahrung in der Pharmaindustrie mit und wird die kommerzielle Strategie des Unternehmens, einschließlich Vertrieb, Marketing und Geschäftsentwicklung, überwachen.
Von 2020 bis 2024 gründete und leitete Roy die kanadischen Aktivitäten von Shilpa Medicare und war zuvor von 2014 bis 2020 Vizepräsident für Geschäftsentwicklung und Vertrieb bei Intas Pharmaceuticals. Er verfügt über einen Executive MBA von der John Molson School of Business, einen M.Sc. von der Université de Montréal und einen Bachelor of Commerce in Wirtschaft von der Concordia University.
Roys Fachwissen umfasst Lizenzierung, Vertrieb, regulatorische Angelegenheiten, Betrieb und Programmmanagement in der Pharma- und Biotechnologiebranche. Dr. Steve Slilaty, CEO von Sunshine Biopharma, äußerte Vertrauen, dass Roys strategische Vision und Erfahrung für das Wachstum und die Markterweiterung des Unternehmens wichtig sein werden.
- Appointment of experienced CCO with over 20 years in pharmaceutical industry
- Strong leadership background in founding and managing pharmaceutical operations
- Extensive experience in business development, sales, and regulatory affairs
- Track record of achieving revenue growth and market expansion at major pharmaceutical companies
- None.
FORT LAUDERDALE, FL / ACCESSWIRE / January 15, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals is pleased to announce the appointment of Mr. Michel Roy as its new Chief Commercial Officer (CCO), effective immediately. Mr. Roy brings a wealth of experience and a proven track record of success in driving commercial growth and strategic initiatives.
In this role, Mr. Roy will be responsible for overseeing the Company's commercial strategy, including sales, marketing, and business development. With over 20 years of experience in the pharmaceutical industry, Mr. Roy has held various leadership positions at major international pharmaceutical companies, where he successfully led teams to achieve significant revenue growth and market expansion.
From 2020 to 2024, Mr. Roy founded and led the Canadian operations of Shilpa Medicare Ltd., a prominent pharmaceutical company based in Raichur, Karnataka, India. Shilpa specializes in manufacturing and selling active pharmaceutical ingredients (APIs), intermediates, and formulations, with a strong presence in oncology APIs, drug delivery systems, peptides, and specialty chemicals. Previously, from 2014 to 2020, Mr. Roy was Vice President, Business Development and Sales for Intas Pharmaceuticals Ltd., a major pharmaceutical company with a strong presence in over 85 countries. Intas is headquartered in Ahmedabad, India. While at Intas, Mr. Roy was responsible for the strategic planning, business development, sales, financial management and regulatory affairs. At the beginning of his career, Mr. Roy worked as a consultant for various international Contract Research Organization (CRO) companies.
Mr. Roy is a results-driven professional with considerable business development experience in the pharmaceutical and biotechnology sectors including licensing, sales, regulatory affairs, operations and program management. His strong negotiation and communication skills, coupled with an in-depth knowledge of all facets of the drug development process contribute to a stellar reputation as a dynamic leader who produces superior results.
Mr. Roy received his Executive Master of Business Administration (EMBA) from John Molson School of Business (Concordia University) in 2010 and his Master of Science (M.Sc.) from Université de Montréal in 1999. He also received a Bachelor of Commerce degree with a major in economics from Concordia University in 1990.
"We are thrilled to welcome Mr. Roy to our executive team," said Dr. Steve Slilaty, CEO of Sunshine Biopharma. "Mr. Roy's extensive experience and strategic vision will be invaluable as we continue to drive our commercial efforts and expand our market presence. We are confident that he will play a key role in our Company's growth and success."
"I am honored to join Sunshine Biopharma and work alongside such a talented team," said Mr. Roy. "I am eager to leverage my experience and expertise to drive our commercial strategy and help the Company achieve its ambitious goals."
About Sunshine Biopharma Inc.
Sunshine Biopharma currently has 65 generic prescription drugs on the market in Canada and 29 additional drugs scheduled to be launched in 2025. Among the new drugs to be launched is NIOPEG®, a biosimilar of NEULASTA®. Like NEULASTA®, NIOPEG® is a long-acting form of recombinant human granulocyte colony-stimulating factor (filgrastim). It is indicated to decrease the incidence of infection in patients with non-myeloid malignancies receiving anti-neoplastic therapy.
In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) SBFM-PL4, a small molecule inhibitor of PLpro protease for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.
All registered trademarks are the property of their respective owners.
Safe Harbor Forward-Looking Statements
This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.
For additional information, please contact:
Mr. Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
SOURCE: Sunshine Biopharma, Inc.
View the original press release on accesswire.com
FAQ
When did Michel Roy join Sunshine Biopharma (SBFM) as CCO?
What is Michel Roy's previous experience before joining SBFM?
What are Michel Roy's responsibilities as CCO at SBFM?
What educational qualifications does SBFM's new CCO Michel Roy hold?
